Dermtech, inc. (CNAC)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16
Cash flows from operating activities:
Net loss

-7,001,000

-

-

-

-5,156,000

-

-

-

-

-

-

-

-

-

-

-

Net (loss) income

-

-

-

-138,794

-4,916

503,566

2,020

443,788

389,965

251,706

246,452

-31,716

0

0

-30

-30

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

60,000

-

-

-

19,000

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

1,022,000

-

-

-

258,000

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt discount and issuance costs

-

-

-

-

1,781,000

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

-

-

-

-

185,000

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

495,000

-

-

-

-302,000

-

-

-

-

-

-

-

-

-

-

-

Inventory

40,000

-

-

-

-1,000

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-86,000

-

-

-

72,000

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued compensation

-714,000

-

-

-

49,000

-

-

-

-

-

-

-

-

-

-

-

Accrued liabilities and deferred revenue

-315,000

-

-

-

-73,000

-

-

-

-

-

-

-

-

-

-

-

Interest earned on marketable securities held in Trust Account

-

-

-

70,854

716,567

835,712

661,182

649,640

481,282

360,898

351,090

14,796

0

0

0

0

Unrealized (gain) loss on securities held in Trust Account

-

-

-

3,220

92,387

-852

15,510

-47,682

-9,567

-11,862

0

-23,987

0

0

0

0

Reduction of deferred underwriting fee

-

-

-

718,750

-

-

-

0

-

-

-

-

-

-

-

-

Prepaid expenses

-

-

-

-5,507

10,076

-36,324

10,001

-25,999

26,420

-30,618

-899

98,600

0

0

0

0

Accounts payable and accrued expenses

-

-

-

900,406

809,456

81,035

533,025

67,789

3,839

13,892

-40,864

49,488

-

-

-

-

Net cash used in operating activities

-7,397,000

-6,080,000

-8,979,295

-25,705

-2,706,000

-213,944

-151,639

-64,382

-104,331

-52,820

-144,603

-71,637

-

-

-

-

Cash flows from investing activities:
Purchases of property and equipment

175,000

-

-

-

6,000

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-30

Investment of cash in Trust Account

-

-

-

-

-

-

-

-

0

0

0

145,187,500

0

0

0

0

Net cash used in investing activities

-175,000

-

-

-

-6,000

-

-

-

0

0

0

-145,187,500

-

-

-

-

Cash flows from financing activities:
Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from sale of Units, net of underwriting discounts paid

-

-

-

-

-

-

-

-

0

0

0

140,875,000

0

0

0

0

Proceeds from sale of Private Units

-

-

-

-

-

-

-

-

0

0

0

5,612,500

0

0

0

0

Advances received from related party

-

-

-

10,500

1

24,999

0

0

0

0

21,790

140,465

56,750

0

0

0

Repayment of advances from related party

-

-

-

-

-

-

-

-

0

0

14,931

304,266

0

0

14,631

0

Payments of issuance costs in connection with Form S-1 registration statement

77,000

-

-

-

-

-

-

-

0

0

0

344,725

31,750

2,254

0

1,750

Proceeds from exercise of common stock warrants

11,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

253,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

60,120,000

174,000

165,352,133

10,500

-136,914,633

24,999

0

0

0

0

6,859

145,978,974

-

-

-

-

Net increase/(decrease) in cash and cash equivalents

52,548,000

-

-

-

-2,712,000

-

-

-

-

-

-

-

-

-

-

-

Supplemental cash flow information:
Purchases of property and equipment recorded in accounts payable

644,000

-

-

-

4,000

-

-

-

-

-

-

-

-

-

-

-

Non-cash investing and financing activities
Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,750

Net change in cash

-

-

-

-15,205

-14,489

-188,945

-151,639

-64,382

-104,331

-52,820

-137,744

719,837

25,000

0

-14,661

-1,780

Offering costs charged to additional paid in capital

-

-

-

-

-

-

-

-

0

0

0

301,278

0

0

0

0

Deferred underwriting fee payable

-

-

-

-

-

-

-

-

0

0

0

5,031,250

0

0

0

0

Initial classification of ordinary shares subject to possible redemption

-

-

-

-

-

-

-

-

0

0

0

135,963,594

0

0

0

0

Change in value of ordinary shares subject to possible redemption

-

-

-

138,798

-4,912

503,568

2,011

443,788

389,965

251,706

246,457

-31,326

0

0

0

0

Private placement
Proceeds from issuance of common stock in connection with private placement offering, net

23,891,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series B-1 Convertible Preferred Stock
Proceeds from issuance of Convertible Preferred Stock, net

30,971,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series B-2 Convertible Preferred Stock
Proceeds from issuance of Convertible Preferred Stock, net

5,071,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Affiliated Entity [Member]
Accounts payable paid by related party under the form of promissory notes

-

-

-

69,559

-

-

-

0

-

-

-

-

-

-

-

-